The Women's Health Company

Hologic, Inc. (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products dedicated to serving the healthcare needs of women throughout the world.

Historically, Hologic developed, manufactured, and marketed products focused on mammography, breast care, and osteoporosis assessment. In 2007, we expanded our focus and now provide a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arms for extremity imaging, and molecular diagnostic products including human papillomavirus (HPV) testing and reagents for a variety of DNA and RNA analysis applications. We are proud of this achievement and conscious of the responsibility that our leadership position brings with it. We believe that the health issues facing women today deserve and demand the singular dedication of a passionate company.

Our core business units are focused on breast health, diagnostics, gynecological surgical, and skeletal health.

Breast Health

At Hologic, our focus and concentration on breast cancer is unmatched. No other major healthcare company devotes a higher percentage of its resources to the development and deployment of screening, diagnostic and therapeutic technologies to meet the challenges of this disease.

Breast surgeons, radiation oncologists and related healthcare professionals have come to rely on our continual advances in digital mammography, biopsy technologies and radiation-focused breast conservation therapy.

Our Selenia^® digital mammography systems and SecurView™ diagnostic workstations are leading the industry in the transition from analog to a digital environment. More than a single technology, Selenia digital mammography represents an integrated suite of technical advances, pushing the science of breast cancer detection forward. Our SecurView workstations can provide clinicians with R2™ computer-aided detection, a sophisticated tool to help find cancers at the earliest stages. For added comfort, our MammoPad^® breast cushion offers a softer, warmer mammogram to help lower the patients' anxiety allowing the technologist to obtain more of the chest wall in the image and ensure even compression of the breast.

If a suspicious lesion is detected, we support the next clinical steps: our ATEC^®, Eviva™ and Celero^® breast biopsy systems, coupled with our MultiCare^® Platinum prone biopsy table and StereoLoc^® II upright biopsy platform, provide clinicians with easier and more effective access to lesions with fewer needle insertions.

Should cancer be detected in its early stages, many women are candidates for the Hologic MammoSite^® radiation therapy system, a unique and welcomed clinical option, and a patient-friendly alternative to traditional whole breast radiation.

Throughout the developed worlds, our breast cancer screening solutions and interventional therapies are the preferred choice for large numbers of physicians, administrators and technologists. Beyond that, as an extension of our global commitment to women's health, we are supporting - with outright contributions of equipment - programs in Tanzania, Nicaragua, Thailand, South Africa, and other countries. Through this work, many women are receiving mammograms for the first time in their lives.

Diagnostics

We believe that women deserve a better answer. We take great pride in the screening and diagnostic capabilities that we have developed for physicians focused on prenatal and gynecological health.

The most widely known is the ThinPrep^® Pap test and Imaging system. For women, it means confidence: ThinPrep technology has set new standards for cervical cancer screening that both women and the medical community have come to rely on. With the ThinPrep Pap test, there are much higher detection levels for precancerous cells, giving physicians and patients more time to undertake appropriate treatment.

A pregnant woman has special concerns: her baby's health, her own health. Our FullTerm™ fetal fibronectin test gives obstetricians and gynecologists a clear picture of preterm birth probabilities - valuable information to support treatment options for the mother if necessary. We offer a second important test for women during pregnancy called InPlex^® CF: a molecular test that can identify genetic mutations associated with cystic fibrosis in both the mother and the unborn child.

HPV is the most common sexually transmitted disease in the United States and is recognized as the cause of most cervical cancers. To help prevent the onset of disease, the American College of Obstetrics and Gynecology (ACOG) suggests routine Pap and HPV testing for women over the age of 30 to identify women most likely to develop cervical cancer.

In early 2009, the U.S. Food and Drug Administration (FDA) approved the Cervista™ HPV HR (high-risk) screening and the Cervista HPV 16/18 genotyping tests. Cervista HPV HR, designed to detect the 14 high-risk types of human papillomavirus (HPV) known to cause cervical cancer, is the first HPV DNA test approved by the FDA in more than 10 years. Cervista HPV 16/18 is the first HPV test approved for genotyping for HPV types 16 and 18, known to be associated with approximately 70 percent of all cervical cancers in the United States. Both of these HPV tests complement our ThinPrep Pap test platform for early detection of cervical cancer.

Our Cellient™ automated cell block system is the first commercially available fully automated system that allows individual cells or small tissue samples to be processed for histological examination. The vacuum-assisted filtration concentrates available cells within the block. The result is diagnostically useful, high-quality blocks that are created in less than an hour and can be reviewed efficiently.

Gynecological Surgical Health

We continue to support a woman's gynecological health past her child-bearing years. NovaSure^® endometrial ablation is the market-leading technology and preferred clinical procedure for treating the condition of menorrhagia. Thanks to the NovaSure system, nearly one million women have been able to dramatically improve the quality of their lives, freed from the debilitating impact of excessive menstrual bleeding.

Our Adiana^® transcervical sterilization system, a form of permanent female contraception intended as an alternative to tubal ligation, is currently under review by the FDA.

Skeletal Health

In the U.S. roughly four out of ten white women over age 50 will experience a hip, spine, or wrist fracture sometime during the remainder of their lives. Looking ahead, the lifetime risk of fractures will increase for all ethnic groups as people live longer. Early detection and treatment can mean a lifetime of health and vitality for women.

Osteoporosis is often a silent thief - when she least expects it; osteoporosis robs a woman of her vitality, her confidence, her spirit. Helping women fight this disease requires especially sensitive care from their physicians - supported by early detection and appropriate treatment to rebuild strong and healthy bones.

Our work in the detection of osteoporosis is one more example of our special commitment to addressing those health challenges that threaten women most severely.

We pioneered dual x-ray bone densitometry technology, which has become the industry standard for assessing bone health. Using our Discovery™ system, clinicians can identify fractures not discernible by normal examinations. An added benefit of these advances is the growing use of the same technologies to measure body composition and support the diagnosis of heart disease. Today there is no definitive cure for osteoporosis. But we will continue to make state-of-the art detection and diagnosis solutions until medical science can develop an answer.

Emerging Technologies

One area that is receiving a great deal of attention in both Hologic and the medical press is our work on breast tomosynthesis. Tomosynthesis makes it possible to obtain three-dimensional images of the breast and to view one slice at a time by removing the images of the overlying and underlying tissues that confuse an ordinary breast x-ray. The greater clarity of the resulting image is expected to lead to the achievement of important clinical benefits, such as increasing the breast cancer detection rate and decreasing the number of false positives that result in unnecessary and emotionally stressful call backs for additional examinations. Hologic Selenia Dimensions™, our breast tomosynthesis offering, is commercial in Europe and other countries and awaiting FDA approval in the U.S.

Every year, Hologic spends tens of millions of dollars in research and development to advance the field of women's healthcare. As our clinical areas expand, we are taking on a broader range of problems, but our goal is always the same: to deliver innovative technologies that result in better outcomes for women.

Worldwide Operations

With centers of operation in North America, Europe, Central America, Australia, and Asia, Hologic is focused on extending its medical systems and solutions to benefit women around the world. We have the strength and resources of a billion dollar company and the vision of leaders committed to a broad spectrum of women's health issues. We have nearly 4,000 employees driven toward breakthrough achievements in research, product development, and the worldwide distribution of healthcare solutions.

And we have the unwavering partnerships of thousands of healthcare professionals who match our dedication to extending and enriching the lives of women everywhere.

Together we cannot fail.